Sat, Dec 20, 2014, 9:14 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Zumiez, Inc. Message Board

theguywho2 68 posts  |  Last Activity: Oct 20, 2014 10:37 AM Member since: Mar 23, 2005
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • SUNNYVALE, Calif., Oct. 20, 2014 (GLOBE NEWSWIRE) -- Alliance Fiber Optic Products, Inc. (AFOP), an innovative supplier of fiber optic components, subsystems, and integrated modules for the optical network equipment market, today announced that it ranked 40th in Forbes' annual list of "America's Best 100 Small Companies". AFOP has appeared on Forbes list four times since 2010. Forbes named AFOP one of the "Most Trustworthy Companies" in 2010, and one of the "America's Best 100 Small Companies "in 2012 and 2013.

    The Forbes "America's Best 100 Small Companies" list selected the top 100 publicly traded companies with sales under $1 billion, based on earnings growth, sales growth and return on equity in the past 12 months and over five years. Forbes' methodology also factors in each company's stock performance versus its peer group during the past 12 months. The full list can be found athttp://www.forbes.com/best-small-companies/list/.

    "What a great accomplishment for AFOP to make the list again this year," commented Peter Chang, President and CEO of AFOP. "It is a particular honor to be in such good company with other distinguished organizations also selected in 2014."

    Forbes commented, "Small caps present tremendous opportunities for investors with faster growth potential in many cases versus multi-billion dollar conglomerates. Each year Forbes looks to identify up-and-coming companies that have displayed strong, consistent growth in our feature on America's Best Small Companies."

  • theguywho2 theguywho2 Sep 11, 2014 9:44 AM Flag

    Go Roth !

  • theguywho2 by theguywho2 Sep 9, 2014 1:37 PM Flag

    Applied Optoelectronics Reports Fifth Consecutive Quarter of Record Revenue

    Second Quarter 2014 Highlights
    -- Record revenue of $32.7 million grew 67% year-over-year and 31%
    sequentially

    -- Data center revenue grew 170% year-over-year and 55% sequentially to
    reach a new record of $17.9 million

    -- CATV revenue of $10.6 million increased 1% year-over-year and 9%
    sequentially

    -- Record fiber-to-the-home revenue of $3.1 million grew 339% year-over-year
    and 40% sequentially

  • theguywho2 by theguywho2 Sep 5, 2014 11:32 AM Flag

    Keryx Biopharmaceuticals Receives FDA Approval of Ferric Citrate, a New, Oral Iron-Based Treatment for Dialysis Patients With Hyperphosphatemia
    Fri Sep 05 11:18:12 2014 EDT
    NEW YORK, Sep 05, 2014 (GLOBE NEWSWIRE via COMTEX News Network) --

    Ferric Citrate: Highly Effective at Controlling Serum Phosphorus Levels, With
    Unique Pharmacodynamic Properties
    Conference Call Scheduled for Noon Today
    Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") today announced
    that the U.S. Food and Drug Administration (FDA) approved Ferric Citrate (formerly
    known as Zerenex) for the control of serum phosphorus levels in patients with chronic
    kidney disease (CKD) on dialysis.

  • The interim analysis was performed on data from the first 50% of patients
    who completed the study. The purpose of the interim analysis was to allow for a
    sample size adjustment if necessary to maintain appropriate statistical power to
    detect a treatment effect between Clonidine Topical Gel and placebo.
    BDSI views the outcome of the analysis as very encouraging. As a result
    of the interim analysis, a total of approximately 80 additional patients will be
    added to the ongoing trial in an effort to maintain 90% percent power to detect
    a statistically significant difference between Clonidine Topical Gel and placebo.
    The analysis was executed by an independent biostatistician.
    "We are encouraged by the outcome of the interim analysis," stated Dr. Andrew
    Finn, Executive Vice President of Product Development at BDSI. "The additional patients
    not only allow us to maintain the probability of ultimately meeting the study's
    endpoints, but given that the initial study enrollment was about three months ahead
    of schedule, we still anticipate having top-line results by the end of the first
    quarter of 2015. In addition, the expanded sample size will provide an adequate
    number of subjects to complete the required long-term safety study that will be
    part of our NDA package. Also part of the NDA will be a second pivotal trial that
    we anticipate starting in early 2015."
    "The outcome of the interim analysis is significant because it utilized actual
    study data to make a sample size adjustment to maintain the probability of a successful
    outcome," said Dr. Mark A. Sirgo, President and Chief Executive Officer. "Based
    on this information we will continue to progress other aspects of the clinical development
    program necessary for the NDA."

  • Is anyone following this company ?

  • theguywho2 by theguywho2 Jun 27, 2014 12:28 PM Flag

    Apparently shorts are driven by a greater greed even though it appears now that failure is not eminent. With a pending squeeze pending, it stands to reason why they just won't let it go. Sooner or later there will be an event to shake up this log jam.

    Sentiment: Hold

  • theguywho2 by theguywho2 Jun 25, 2014 5:07 PM Flag

    The company now has a fully-functional, roll-to-roll pilot production line comprised of a plating line at the company's Texas facility, and printing, final testing and packaging at the Kodak facility, a state-of-the-art manufacturing and testing facility within the Eastman Business Park in Rochester, New York. UniPixel and Kodak have begun conducting roll-to-roll pilot manufacturing and yield studies on the overall process, as well as technology transfer of the modified process to production plating assets in the Kodak facility.

  • theguywho2 by theguywho2 Jun 10, 2014 3:13 PM Flag

    Houston we don't have a problem !

  • Reply to

    18$ price target,

    by espo1900 Jun 9, 2014 12:25 PM
    theguywho2 theguywho2 Jun 9, 2014 12:55 PM Flag

    Not gonna happen.

  • theguywho2 by theguywho2 Jun 4, 2014 3:45 PM Flag

    The short move was from 37 to 5. That's it, what are you waiting for?
    Another dollar, dollar and a half? Not gonna happen. There is a lot of shares to cover out there. The ones
    who wait the longest, will give back most of the profits. Buying back the borrowed stock is inevitable. Better get crackin' ! Just saying'

  • theguywho2 theguywho2 May 14, 2014 4:52 PM Flag

    Float: 329 million shares Short interest: 28 million shares (8+%)

  • Reply to

    All the Shorts

    by theguywho2 May 9, 2014 2:40 PM
    theguywho2 theguywho2 May 9, 2014 3:34 PM Flag

    Yahoo finance headline shows UNXL as one of the "break-out stocks" of the week

  • theguywho2 by theguywho2 May 9, 2014 2:40 PM Flag

    Hate their run to end, still hanging around trying to poke holes in everything. Lazy mind sets, don't know how to pick a good stock, too much effort to look for another vulnerable company to short, so they stay and post
    here over and over again. Sad. Whether it takes 6 months, a year, or maybe a little more, this product is going to roll out. Nobody that is long is going to sell here, they've waited this long so why would they sell now? Half the float is long, half is short. The short move was from 37 to 5. That's it, what are you waiting for?
    Another dollar, dollar and a half? Not gonna happen. There is a lot of shares to cover out there. The ones
    who wait the longest, will give back most of the profits. Buying back the borrowed stock is inevitable. Better get crackin' ! Just saying'.

  • theguywho2 by theguywho2 May 9, 2014 11:43 AM Flag

    at the end of the tunnel, short positions should start to unwind. For those looking to go long,
    BUY LOW.........SELL HIGH ! ! !

  • Reply to

    New 52 week low $9.50

    by rhatche38 Apr 28, 2014 12:14 PM
    theguywho2 theguywho2 Apr 30, 2014 1:06 PM Flag

    Saw that....
    SeaChange International’s ( SEAC ) share price has entered into oversold territory with an RSI value of 28.2. The Zacks Consensus Estimate for SeaChange for the full year period has improved 12 cents over the past two months to 17 cents per share. Currently, SeaChange has a Zacks Rank #2 (Buy), suggesting that now might be a good time to get in on ( SEAC ) after its recent drop.

  • Reply to

    New 52 week low $9.50

    by rhatche38 Apr 28, 2014 12:14 PM
    theguywho2 theguywho2 Apr 29, 2014 1:07 PM Flag

    I hear you. Thing is, who is selling here? Volume at 1:00PM on Tuesday is a
    meager 136M. Why would someone sell around the 52-week low? I suppose the
    12% you mention in public hands means high volatility even on low volume.
    You are right about the fact that it would be nice for the company to buy some shares back here to show some support. If they lose institutional support here
    it could spell more trouble.

  • Reply to

    short interest

    by ydobrovic Apr 28, 2014 1:48 PM
    theguywho2 theguywho2 Apr 28, 2014 3:56 PM Flag

    agree

  • theguywho2 theguywho2 Apr 28, 2014 3:38 PM Flag

    Yes, bring on that conference call !

  • Reply to

    New 52 week low $9.50

    by rhatche38 Apr 28, 2014 12:14 PM
    theguywho2 theguywho2 Apr 28, 2014 3:06 PM Flag

    This from the last CC: We continue to expect that revenue will likely grow only in
    the second half of fiscal 2015 and remain flat to down for the full year relative
    to fiscal 2014."
    Anthony Dias, CFO, SeaChange, said, "While revenues and operating margins
    in the first half of fiscal 2015 are expected to be lower than the corresponding
    period in fiscal 2014, we are targeting higher profitability for the full fiscal
    year, driven by the growth in our next generation products and the reduction in
    incremental costs related to the rollout of large development projects."
    SeaChange ended its fourth quarter fiscal 2014 with cash, cash equivalents
    and marketable securities of $128.1 million and no debt outstanding, compared to
    $126.4 million at the end of the third quarter of fiscal 2014. Toward the end of
    the fourth quarter, SeaChange implemented a 10b5-1 plan to execute on its $25 million
    stock buyback authorization.

ZUMZ
37.31-0.62(-1.63%)Dec 19 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Under Armour, Inc.
NYSEFri, Dec 19, 2014 4:04 PM EST
ImmunoGen, Inc.
NASDAQFri, Dec 19, 2014 4:00 PM EST
Hertz Global Holdings, Inc.
NYSEFri, Dec 19, 2014 4:00 PM EST